| Open Document File Size: 2,44 MBShare Result on Facebook
Company AEs / TDI / Forest Laboratories Inc. / / Continent Europe / / Country Belgium / United States / Canada / South Africa / Peru / / Event FDA Phase / / Facility FDA White Oak Campus / / IndustryTerm inhaler device / chemical and enzymatic hydrolysis / biologic product / manufacturing / food remnants / chemical / inhalation products / combination products / / MedicalCondition laryngospasm / bronchospasm / dyspnea claim / COPD / disease / urinary retention / dyspnea / emphysema / chronic obstructive pulmonary disease / stroke / cardiovascular disease / Transitional Dyspnea Index / severe COPD / myocardial infarction / constipation / dyspnea using / bronchoconstriction / chronic bronchitis / / NaturalFeature Clinical Pharmacology Forest / Toxicology Forest / Aclidinium Forest / / Organization PULMONARY ALLERGY DRUGS ADVISORY COMMITTEE / Food and Drug Administration / Division of Pulmonary / Allergy / and Rheumatology Products / Review Division / FDA / ALLERGY DRUGS ADVISORY COMMITTEE / Advisory Committee / Maryland NDA / / Person Adverse Cardiac / Susan Limb / Ann Intern / / Position Major / Medical Team Leader / / Product ipratropium bromide / Spiriva / Phase-2 / FEV1 / M3 / MDCL23 / US / Spiriva Handihaler® / / PublishedMedium the NDA review / / Technology pharmacokinetics / /
SocialTag |
PULMONARY ALLERGY DRUGS ADVISORY COMMITTEE MEETING February 23, 2012 FDA White Oak Campus, The Great Room White Oak Conference Center Silver Spring, Maryland